Marie Lafleur is a senior partner and member of the Montréal office's Intellectual Property Litigation team. She regularly appears before the Federal Court of Canada and the provincial courts of the Province of Québec in litigation involving the infringement and the validity of patents, trademarks, copyrights and industrial designs as well as in matters concerning trade secrets and unfair competition. Her expertise extends to all extraordinary remedies, including seizures before judgement and injunctions and she is fully versed in all aspects of conflict resolution, as well as dispute resolution mechanisms.
More particularly, Ms. Lafleur is specialized in the litigation of pharmaceutical patents and patents on biologics. She is lead counsel in NOC cases and has represented companies in numerous proceedings seeking to prohibit the Minister of Health Canada from issuing notices of compliance which would allow the sale of generic versions of patented drugs, such as citalopram, escitalopram, doxylamine/pyridoxine, cyclosporine, omeprazole, diltiazem, divalproex and terazosin, among others. She has been involved in judicial review applications dealing with the addition or the removal of patents from the patent register as well as in patent litigation concerning the infringement and the validity of pharmaceutical patents.